NextCure (NASDAQ:NXTC) Releases Earnings Results, Beats Estimates By $0.84 EPS

NextCure (NASDAQ:NXTC) released its quarterly earnings data on Wednesday. The company reported ($3.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.06) by $0.84, Zacks reports.

NextCure Stock Performance

Shares of NextCure stock traded up $0.18 on Thursday, reaching $9.81. The company had a trading volume of 6,833 shares, compared to its average volume of 50,364. The firm’s 50 day moving average price is $7.12 and its two-hundred day moving average price is $6.02. The firm has a market cap of $26.25 million, a PE ratio of -0.38 and a beta of 1.48. NextCure has a 52-week low of $2.69 and a 52-week high of $19.20.

Wall Street Analysts Forecast Growth

NXTC has been the subject of a number of analyst reports. Piper Sandler set a $15.00 target price on shares of NextCure and gave the company an “overweight” rating in a research report on Tuesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research note on Friday, October 31st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $25.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP boosted its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 758,141 shares of the company’s stock after acquiring an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.